Last reviewed · How we verify
Stromectol ® tablets
At a glance
| Generic name | Stromectol ® tablets |
|---|---|
| Sponsor | Humanis Saglık Anonim Sirketi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ivermectin Safety in Small Children (PHASE2)
- Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (PHASE2)
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration (PHASE2, PHASE3)
- Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura (PHASE3)
- Efficacy and Safety of IVM/ALB Co-administration (PHASE2, PHASE3)
- Efficacy and Safety of MOX/ALB Co-administration (PHASE3)
- Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions (PHASE1)
- Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stromectol ® tablets CI brief — competitive landscape report
- Stromectol ® tablets updates RSS · CI watch RSS
- Humanis Saglık Anonim Sirketi portfolio CI